OTCMKTS:MYCOF Mydecine Innovations Group (MYCOF) Stock Price, News & Analysis → Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad) Free MYCOF Stock Alerts $0.01 0.00 (-24.49%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$0.0111▼$0.011150-Day Range$0.00▼$0.0252-Week Range$0.00▼$0.29Volume168 shsAverage Volume21,416 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Mydecine Innovations Group alerts: Email Address Ad Behind the MarketsForget Bitcoin: This $8 Stock Is the Next Big Thing4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Mydecine Innovations Group Stock (OTCMKTS:MYCOF)Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.Read More MYCOF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYCOF Stock News HeadlinesMay 3, 2024 | finanznachrichten.deMydecine Innovations Group Inc - Mydecine applies for management cease trade orderMay 3, 2024 | finanznachrichten.deMydecine Innovations Group Inc - Management cease trade orderMay 3, 2024 | Weiss Ratings (Ad)[URGENT] DO NOT Touch These AI Stocks!Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?April 18, 2024 | finance.yahoo.comMydecine Innovations Group Inc (0NF0.BE)April 17, 2024 | finance.yahoo.comMydecine Innovations Group Inc (0NF0.MU)April 17, 2024 | stockhouse.comMydecine Innovations Group Inc. Announces Closing Of Share For Debt SettlementApril 9, 2024 | uk.finance.yahoo.comMydecine Innovations Group Inc - SHARE FOR DEBT SETTLEMENTMarch 28, 2024 | uk.finance.yahoo.comMydecine Innovations Group Inc - Mydecine Innovations Group Inc. Announces Closing of Share for Debt SettlementMay 3, 2024 | Weiss Ratings (Ad)[URGENT] DO NOT Touch These AI Stocks!Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?March 20, 2024 | finance.yahoo.comMydecine Innovations Group Inc. Announces Share for Debt SettlementFebruary 7, 2024 | finance.yahoo.comMydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of CompoundsFebruary 2, 2024 | finance.yahoo.comMydecine Innovations Group Announces Director ResignationDecember 18, 2023 | uk.finance.yahoo.comMydecine Innovations Group Inc - Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 CompoundDecember 18, 2023 | finance.yahoo.comMydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 CompoundNovember 29, 2023 | finanznachrichten.deMydecine Innovations Group Inc.: Mydecine Announces Update Regarding the Special Access ProgramNovember 28, 2023 | finance.yahoo.comMydecine Announces Update Regarding the Special Access ProgramNovember 17, 2023 | finance.yahoo.comCanadian Securities Exchange Reports October 2023 Performance FiguresOctober 31, 2023 | finance.yahoo.comMydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription AgreementsOctober 26, 2023 | finanznachrichten.deMydecine Innovations Group Inc.: Mydecine Provides Q4 2023 Business UpdateOctober 26, 2023 | financialpost.comMydecine Provides Q4 2023 Business UpdateOctober 25, 2023 | lse.co.ukMydecine Innovations Group Inc Share Price (MYIG.PL)October 16, 2023 | proactiveinvestors.comMydecine Innovations Group gearing up for human trials after completing Aquis listingOctober 13, 2023 | finanznachrichten.deMydecine Innovations Group Inc - Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UKOctober 12, 2023 | benzinga.comPsychedelic-Based Drugs Biotech Company Begins Trading On UK's AQSE Growth MarketOctober 12, 2023 | finanznachrichten.deMydecine Innovations Group Inc.: Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UKOctober 12, 2023 | finance.yahoo.comMydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UKOctober 5, 2023 | finance.yahoo.comMydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEOSee More Headlines Receive MYCOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mydecine Innovations Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/16/2021Today5/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:MYCOF CUSIPN/A CIKN/A Webwww.mydecine.com Phone(604) 687-2038FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. David Joshua Bartch (Age 36)Co-Founder, CEO, President & Chairman of the Board Comp: $322.62kMr. Robert Roscow M.A.Co-Founder, Chief Scientific Officer & DirectorMr. Damon MichaelsCo-Founder & COOMr. John Charles Ross CA (Age 66)CPA, M.B.A., CFO & Corporate Secretary Comp: $6.68kMr. Sanford M. SteinChief Compliance Officer & General CounselDr. Rakesh Jetly FRCPCM.D., Chief Medical OfficerMorgan KervitskyDirector of MarketingMr. Michel RudolphiePresident of the European OperationsMr. William CookInterim CEO & Technical Director of Mindleap Health Inc.More ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors MYCOF Stock Analysis - Frequently Asked Questions How have MYCOF shares performed in 2024? Mydecine Innovations Group's stock was trading at $0.0149 on January 1st, 2024. Since then, MYCOF stock has decreased by 25.5% and is now trading at $0.0111. View the best growth stocks for 2024 here. How were Mydecine Innovations Group's earnings last quarter? Mydecine Innovations Group Inc. (OTCMKTS:MYCOF) issued its earnings results on Tuesday, November, 16th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.50. When did Mydecine Innovations Group's stock split? Mydecine Innovations Group's stock reverse split before market open on Thursday, April 21st 2022. The 1-50 reverse split was announced on Thursday, April 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Mydecine Innovations Group? Shares of MYCOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MYCOF) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersThe AI stock to buy right nowStockEarningsCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profits$5,000 Gold?Stansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mydecine Innovations Group Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
